

Jean-Pierre Gerard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3640642/publications.pdf>

Version: 2024-02-01

51
papers

6,855
citations

172457

29
h-index

197818

49
g-index

52
all docs

52
docs citations

52
times ranked

5366
citing authors

#	ARTICLE	IF	CITATIONS
1	Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203. <i>Journal of Clinical Oncology</i> , 2006, 24, 4620-4625.	1.6	1,551
2	Influence of the Interval Between Preoperative Radiation Therapy and Surgery on Downstaging and on the Rate of Sphincter-Sparing Surgery for Rectal Cancer: The Lyon R90-01 Randomized Trial. <i>Journal of Clinical Oncology</i> , 1999, 17, 2396-2396.	1.6	719
3	Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2. <i>Journal of Clinical Oncology</i> , 2010, 28, 1638-1644.	1.6	686
4	Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. <i>Lancet</i> , The, 2018, 391, 2537-2545.	13.7	677
5	Nomograms for Predicting Local Recurrence, Distant Metastases, and Overall Survival for Patients With Locally Advanced Rectal Cancer on the Basis of European Randomized Clinical Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 3163-3172.	1.6	439
6	Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 4558-4565.	1.6	360
7	Improved Sphincter Preservation in Low Rectal Cancer With High-Dose Preoperative Radiotherapy: The Lyon R96-02 Randomized Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 2404-2409.	1.6	306
8	Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 1941-1948.	1.6	305
9	Past, present, and future of radiotherapy for the benefit of patients. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 52-60.	27.6	289
10	Management of inguinal lymph node metastases in patients with carcinoma of the anal canal. <i>Cancer</i> , 2001, 92, 77-84.	4.1	153
11	Interstitial curietherapy in the conservative treatment of anal and rectal cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 1989, 17, 1161-1169.	0.8	103
12	Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1685-1702.	1.0	100
13	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 805-816.	27.6	93
14	Long-term control of T2â€“T3 rectal adenocarcinoma with radiotherapy alone. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 142-149.	0.8	92
15	Endocavitary irradiation for early rectal carcinomas T1 (T2). A series of 101 patients treated with the Papillon's technique. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 34, 775-783.	0.8	82
16	Radiation therapy in the conservative treatment of carcinoma of the anal canal. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 29, 17-23.	0.8	71
17	Radiotherapy alone in the curative treatment of rectal carcinoma. <i>Lancet Oncology</i> , The, 2003, 4, 158-166.	10.7	66
18	Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). <i>Digestive and Liver Disease</i> , 2017, 49, 359-367.	0.9	65

#	ARTICLE	IF	CITATIONS
19	Can we increase the chance of sphincter saving surgery in rectal cancer with neoadjuvant treatments: Lessons from a systematic review of recent randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 21-28.	4.4	59
20	Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. <i>Radiotherapy and Oncology</i> , 2015, 115, 246-252.	0.6	53
21	Pathologic Response, When Increased by Longer Interval, Is a Marker but Not the Cause of a Good Prognosis in Rectal Cancer: 17-year Follow-up of the Lyon R90-01 Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 544-553.	0.8	50
22	Planned organ preservation for early T2-3 rectal adenocarcinoma: A French, multicentre study. <i>European Journal of Cancer</i> , 2019, 108, 1-16.	2.8	49
23	Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials. <i>Radiotherapy and Oncology</i> , 2021, 154, 154-160.	0.6	45
24	Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: Tolerance and efficacy. <i>Radiotherapy and Oncology</i> , 2014, 110, 144-149.	0.6	43
25	Contact X-ray Therapy for Rectal Cancer: Experience in Centre Antoine-Lacassagne, Nice, 2002-2006. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 665-670.	0.8	41
26	Treatment of squamous cell anal canal carcinoma with pulsed dose rate brachytherapy. Feasibility study of a French cooperative group. <i>Radiotherapy and Oncology</i> , 1999, 51, 129-131.	0.6	39
27	Renaissance of contact x-ray therapy for treating rectal cancer. <i>Expert Review of Medical Devices</i> , 2011, 8, 483-492.	2.8	38
28	Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients. <i>European Journal of Cancer</i> , 2017, 72, 124-136.	2.8	36
29	Contact radiotherapy using a 50kV X-ray system: Evaluation of relative dose distribution with the Monte Carlo code PENELOPE and comparison with measurements. <i>Radiation Physics and Chemistry</i> , 2012, 81, 609-617.	2.8	32
30	Organ preservation in rectal adenocarcinoma (T1) T2-T3 Nx M0. Historical overview of the Lyon Sud - Nice experience using contact x-ray brachytherapy and external beam radiotherapy for 120 patients. <i>Acta Oncologica</i> , 2015, 54, 550-556.	1.8	30
31	Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: A retrospective study. <i>Radiotherapy and Oncology</i> , 2006, 79, 75-79.	0.6	29
32	Interstitial high-dose rate brachytherapy as boost for anal canal cancer. <i>Radiation Oncology</i> , 2014, 9, 240.	2.7	22
33	Contact x-ray brachytherapy (Papillon) in addition to chemoradiotherapy to improve organ preservation in early cT2-T3 rectal adenocarcinoma: The 3-year results of OPERA randomized trial (NCT02505750).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3512-3512.	1.6	18
34	Results of age-dependent anal canal cancer treatment: A single centre retrospective study. <i>Digestive and Liver Disease</i> , 2014, 46, 460-464.	0.9	14
35	A multi-centre analysis of adjuvant contact X-ray brachytherapy (CXB) in rectal cancer patients treated with local excision - Preliminary results of the CONTEM1 study. <i>Radiotherapy and Oncology</i> , 2021, 162, 195-201.	0.6	13
36	GEC ESTRO ACROP consensus recommendations for contact brachytherapy for rectal cancer. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 15-22.	1.7	12

#	ARTICLE	IF	CITATIONS
37	Impact of single nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD12/PRODIGE2 phase III trial. International Journal of Cancer, 2019, 145, 3163-3172.	5.1	11
38	A systematic review comparing radiation toxicity after various endorectal techniques. Brachytherapy, 2019, 18, 71-86.e5.	0.5	10
39	A brief history of contact X-ray brachytherapy 50 kVp. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 222-225.	1.4	10
40	Does non-TME surgery of rectal cancer compromise the chance of cure? Preliminary surgical salvage data from OPERA phase III randomized trial.. Journal of Clinical Oncology, 2021, 39, 12-12.	1.6	10
41	Contact X-ray brachytherapy for rectal cancer: Past, present, and future. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2021, 25, 795-800.	1.4	7
42	Clinical response assessment after contact X-Ray brachytherapy and chemoradiotherapy for organ preservation in rectal cancer T2-T3 M0: The time/dose factor influence. Clinical and Translational Radiation Oncology, 2020, 24, 92-98.	1.7	6
43	Clinical outcome of rectal cancer in patients 80 years treated in southern France (PACA region) between 2002 and 2005. Strahlentherapie Und Onkologie, 2012, 188, 383-387.	2.0	5
44	Efficacy and tolerance of high-dose-rate brachytherapy boost after external radiotherapy in the treatment of squamous cell carcinoma of the anal canal. Journal of Contemporary Brachytherapy, 2018, 10, 522-531.	0.9	4
45	Organ preservation for T2-T3 rectal cancer: opportunistic or planned strategy. Oncotarget, 2019, 10, 3431-3432.	1.8	3
46	Targeted Radiotherapy Using Contact X-ray Brachytherapy 50 kV. Cancers, 2022, 14, 1313.	3.7	3
47	Towards a Lyon molecular signature to individualize the treatment of rectal cancer. Prognostic analysis of a prospective cohort of 94 rectal cancers T1-2-3 Nx M0 to be the basis of a molecular signature. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2012, 16, 688-696.	1.4	2
48	Propensity score analysis of radical proctectomy versus organ preservation using contact X-ray brachytherapy for rectal cancer. Clinical and Translational Radiation Oncology, 2022, 33, 70-76.	1.7	2
49	International validation of the Immunoscore-biopsy (IS _B) to guide selection and monitoring of patients treated with watch-and-wait (WW) strategy for rectal cancer.. Journal of Clinical Oncology, 2022, 40, 3517-3517.	1.6	2
50	New Neoadjuvant Treatment Strategies for Non-Metastatic Rectal Cancer (M0). Current Colorectal Cancer Reports, 2015, 11, 289-297.	0.5	0
51	Immunotherapy for rectal carcinoma: Some stimulating data but still a long way to clinical evidence. European Journal of Cancer, 2016, 68, 70-72.	2.8	0